These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1360327)

  • 1. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms.
    Seidman JD; Frisman DM; Norris HJ
    Cancer; 1992 Dec; 70(12):2857-60. PubMed ID: 1360327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA flow cytometric analysis of serous ovarian tumors of low malignant potential.
    Seidman JD; Norris HJ; Griffin JL; Hitchcock CL
    Cancer; 1993 Jun; 71(12):3947-51. PubMed ID: 8508360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
    Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
    Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis.
    Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.
    Ross JS; Yang F; Kallakury BV; Sheehan CE; Ambros RA; Muraca PJ
    Am J Clin Pathol; 1999 Mar; 111(3):311-6. PubMed ID: 10078105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival.
    Raspollini MR; Amunni G; Villanucci A; Castiglione F; Rossi Degl'Innocenti D; Baroni G; Paglierani M; Taddei GL
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):181-6. PubMed ID: 16785787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries.
    Mileo AM; Fanuele M; Battaglia F; Scambia G; Benedetti-Panici C; Mattei E; Mancuso S; Delpino A
    Int J Biol Markers; 1992; 7(1):47-51. PubMed ID: 1349908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.
    Wong YF; Cheung TH; Lam SK; Lu HJ; Zhuang YL; Chan MY; Chung TK
    Gynecol Obstet Invest; 1995; 40(3):209-12. PubMed ID: 8529957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
    Fan QB; Bian ML; Huang SZ
    Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
    Karlan BY; Jones J; Slamon DJ; Lagasse LD
    Gynecol Oncol; 1994 Apr; 53(1):70-7. PubMed ID: 7909787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of HER-2/neu expression in ovarian epithelial tumours.
    Gao D; Lu Y; Lu Y; Wang Y; Zhang B; Wu B
    Zhonghua Bing Li Xue Za Zhi; 2002 Jun; 31(3):268-70. PubMed ID: 12475446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
    Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
    Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
    Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
    Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neu oncogene expression in ovarian tumors: a quantitative study.
    Huettner PC; Carney WP; Naber SP; DeLellis RA; Membrino W; Wolfe HJ
    Mod Pathol; 1992 May; 5(3):250-6. PubMed ID: 1353878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
    Berchuck A; Rodriguez G; Kinney RB; Soper JT; Dodge RK; Clarke-Pearson DL; Bast RC
    Am J Obstet Gynecol; 1991 Jan; 164(1 Pt 1):15-21. PubMed ID: 1670908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.